Publications Archivi - UNIVERSAL PROJECT

Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial

by Musakanya Chingandu | Sep 10, 2026 | Publications

Authors: Kamphuis AEM, Salvadori N, Mujuru HA, Bwakura-Dangarembizi M, Kisitu GP, Matovu F, Kaudha E, Mulindwa A, Jacobs TG, Than-in-at K, Cressey TR, Nardone A, Lallemant M, Colbers A, Burger DM Published in: The Lancet [button...

Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

by Musakanya Chingandu | Aug 10, 2026 | Publications

Authors: Waalewijn H, Bevers LAH, Lewis LL, Louey MD, Kawakatsu S, Zheng Y, Giaquinto C, Nardone A, Burger DM, ter Heine R, Colbers A, Svensson EM. Published in: Clinical Pharmacokinetics [button link="https://link.springer.com/article/10.1007/s40262-026-01671-z"...

Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers

by Musakanya Chingandu | Jul 20, 2026 | Publications

Authors: Kamphuis A.E.M., Burger D, Bevers L.A.H. Published in: Radobud Univeristy

Pharmacokinetics of a Novel Dose Ratio of DTG/FTC/TAF for African Children with HIV (UNIVERSAL1)

by Francesca Mazzetto | Mar 3, 2026 | Publications

Authors: Kamphuis AEM, Mujuru HA, Bwakura-Dangarembizi MF, Kisitu GP, Matovu F, Kaudha E, Mulindwa A, Jacobs TG, Salvadori N, Than-in-at K, Cressey TR, Nardone A, Lallemant M, Burger DM, for the UNIVERSAL1 Trial Team. Presented at: CROI 2026 [button...

Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials

by Musakanya Chingandu | Jul 17, 2025 | Publications

Authors: Amuge P, Jackson C, Bwakura-Dangarembizi M, Kityo C, Lugemwa A, Chabala C, Nyathi M, Nduna B, Musoke P, Yawe I, Kaudha E, Musoro G, Ankunda R, Bbuye D, Violar A, Variava E, Archary M, Cotton M, Cressey RT, Ndebele W, Mulenga V, Mwamabazi M, Szubert A, White...

Optimising Paediatric HIV Treatment: Recent Developments and Future Directions

by Musakanya Chingandu | Oct 28, 2024 | Publications

Authors: Kamphuis A.E.M., Bamford A., Tagarro A., Cressey AT, Bekker A, Amuge P, Mujuru HA, Ndongo AF, Diack A, Compagnucci A, Lallemant M, Colbers A, Turkova A. Published in: Pediatric Drugs [button link="https://link.springer.com/article/10.1007/s40272-024-00656-4"...

Relative bioavailability of dolutegravir (DTG) and emtricitabine/tenofovir alafenamide fumarate (F/TAF) administered as paediatric tablet formulations in healthy volunteers

by Musakanya Chingandu | Sep 18, 2023 | Publications

Authors: Bevers LAH, Kamphuis AEM, van der Wekken-Pas LC, Leisegang R, Lewis L, Burger DM, Colbers A Presented at: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023 [button...